138 related articles for article (PubMed ID: 21224892)
1. Dutch myotonic dystrophy type 2 patients and a North-African DM2 family carry the common European founder haplotype.
Coenen MJ; Tieleman AA; Schijvenaars MM; Leferink M; Ranum LP; Scheffer H; van Engelen BG
Eur J Hum Genet; 2011 May; 19(5):567-70. PubMed ID: 21224892
[TBL] [Abstract][Full Text] [Related]
2. Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect.
Bachinski LL; Udd B; Meola G; Sansone V; Bassez G; Eymard B; Thornton CA; Moxley RT; Harper PS; Rogers MT; Jurkat-Rott K; Lehmann-Horn F; Wieser T; Gamez J; Navarro C; Bottani A; Kohler A; Shriver MD; Sallinen R; Wessman M; Zhang S; Wright FA; Krahe R
Am J Hum Genet; 2003 Oct; 73(4):835-48. PubMed ID: 12970845
[TBL] [Abstract][Full Text] [Related]
3. Ancestral Origin of the First Indian Families with Myotonic Dystrophy Type 2.
Damen M; Schijvenaars M; Schimmel-Naber M; Groothuismink J; Coenen M; Tieleman A
J Neuromuscul Dis; 2021; 8(4):715-722. PubMed ID: 34024776
[TBL] [Abstract][Full Text] [Related]
4. Myotonic dystrophy type 2: human founder haplotype and evolutionary conservation of the repeat tract.
Liquori CL; Ikeda Y; Weatherspoon M; Ricker K; Schoser BG; Dalton JC; Day JW; Ranum LP
Am J Hum Genet; 2003 Oct; 73(4):849-62. PubMed ID: 14505273
[TBL] [Abstract][Full Text] [Related]
5. Myotonic dystrophy type 2 in Japan: ancestral origin distinct from Caucasian families.
Saito T; Amakusa Y; Kimura T; Yahara O; Aizawa H; Ikeda Y; Day JW; Ranum LP; Ohno K; Matsuura T
Neurogenetics; 2008 Feb; 9(1):61-3. PubMed ID: 18057971
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a single nucleotide polymorphism in the ZNF9 gene and analysis of association with myotonic dystrophy type II (DM2) in the Italian population.
Vallo L; Bonifazi E; Borgiani P; Novelli G; Botta A
Mol Cell Probes; 2005 Feb; 19(1):71-4. PubMed ID: 15652222
[TBL] [Abstract][Full Text] [Related]
7. Mutant (CCTG)n expansion causes abnormal expression of zinc finger protein 9 (ZNF9) in myotonic dystrophy type 2.
Raheem O; Olufemi SE; Bachinski LL; Vihola A; Sirito M; Holmlund-Hampf J; Haapasalo H; Li YP; Udd B; Krahe R
Am J Pathol; 2010 Dec; 177(6):3025-36. PubMed ID: 20971734
[TBL] [Abstract][Full Text] [Related]
8. Clinical, electrophysiologic and pathologic findings in 10 patients with myotonic dystrophy 2.
Dabby R; Sadeh M; Herman O; Leibou L; Kremer E; Mordechai S; Watemberg N; Frand J
Isr Med Assoc J; 2011 Dec; 13(12):745-7. PubMed ID: 22332444
[TBL] [Abstract][Full Text] [Related]
9. Myotonic dystrophy type 2.
Finsterer J
Eur J Neurol; 2002 Sep; 9(5):441-7. PubMed ID: 12220374
[TBL] [Abstract][Full Text] [Related]
10. A non-DM1, non-DM2 multisystem myotonic disorder with frontotemporal dementia: phenotype and suggestive mapping of the DM3 locus to chromosome 15q21-24.
Le Ber I; Martinez M; Campion D; Laquerrière A; Bétard C; Bassez G; Girard C; Saugier-Veber P; Raux G; Sergeant N; Magnier P; Maisonobe T; Eymard B; Duyckaerts C; Delacourte A; Frebourg T; Hannequin D
Brain; 2004 Sep; 127(Pt 9):1979-92. PubMed ID: 15215218
[TBL] [Abstract][Full Text] [Related]
11. ZNF9 activation of IRES-mediated translation of the human ODC mRNA is decreased in myotonic dystrophy type 2.
Sammons MA; Antons AK; Bendjennat M; Udd B; Krahe R; Link AJ
PLoS One; 2010 Feb; 5(2):e9301. PubMed ID: 20174632
[TBL] [Abstract][Full Text] [Related]
12. Myotonic dystrophy: emerging mechanisms for DM1 and DM2.
Cho DH; Tapscott SJ
Biochim Biophys Acta; 2007 Feb; 1772(2):195-204. PubMed ID: 16876389
[TBL] [Abstract][Full Text] [Related]
13. The myotonic dystrophy type 2 (DM2) gene product zinc finger protein 9 (ZNF9) is associated with sarcomeres and normally localized in DM2 patients' muscles.
Massa R; Panico MB; Caldarola S; Fusco FR; Sabatelli P; Terracciano C; Botta A; Novelli G; Bernardi G; Loreni F
Neuropathol Appl Neurobiol; 2010 Jun; 36(4):275-84. PubMed ID: 20102514
[TBL] [Abstract][Full Text] [Related]
14. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum.
Day JW; Ricker K; Jacobsen JF; Rasmussen LJ; Dick KA; Kress W; Schneider C; Koch MC; Beilman GJ; Harrison AR; Dalton JC; Ranum LP
Neurology; 2003 Feb; 60(4):657-64. PubMed ID: 12601109
[TBL] [Abstract][Full Text] [Related]
15. Reduction of the rate of protein translation in patients with myotonic dystrophy 2.
Huichalaf C; Schoser B; Schneider-Gold C; Jin B; Sarkar P; Timchenko L
J Neurosci; 2009 Jul; 29(28):9042-9. PubMed ID: 19605641
[TBL] [Abstract][Full Text] [Related]
16. Premutation allele pool in myotonic dystrophy type 2.
Bachinski LL; Czernuszewicz T; Ramagli LS; Suominen T; Shriver MD; Udd B; Siciliano MJ; Krahe R
Neurology; 2009 Feb; 72(6):490-7. PubMed ID: 19020295
[TBL] [Abstract][Full Text] [Related]
17. CCUG repeats reduce the rate of global protein synthesis in myotonic dystrophy type 2.
Schneider-Gold C; Timchenko LT
Rev Neurosci; 2010; 21(1):19-28. PubMed ID: 20458885
[TBL] [Abstract][Full Text] [Related]
18. Effect of the [CCTG]n repeat expansion on ZNF9 expression in myotonic dystrophy type II (DM2).
Botta A; Caldarola S; Vallo L; Bonifazi E; Fruci D; Gullotta F; Massa R; Novelli G; Loreni F
Biochim Biophys Acta; 2006 Mar; 1762(3):329-34. PubMed ID: 16376058
[TBL] [Abstract][Full Text] [Related]
19. Anatomy of a founder effect: myotonic dystrophy in Northeastern Quebec.
Yotova V; Labuda D; Zietkiewicz E; Gehl D; Lovell A; Lefebvre JF; Bourgeois S; Lemieux-Blanchard E; Labuda M; Vézina H; Houde L; Tremblay M; Toupance B; Heyer E; Hudson TJ; Laberge C
Hum Genet; 2005 Jul; 117(2-3):177-87. PubMed ID: 15883838
[TBL] [Abstract][Full Text] [Related]
20. A long PCR-based molecular protocol for detecting normal and expanded ZNF9 alleles in myotonic dystrophy type 2.
Bonifazi E; Vallo L; Giardina E; Botta A; Novelli G
Diagn Mol Pathol; 2004 Sep; 13(3):164-6. PubMed ID: 15322428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
